Cell Biology Program

The Marilyn Resh Lab

Research

Marilyn Resh, PhD
Member

The goal of my laboratory’s research is to understand how fatty acylation influences the structure and function of membrane-bound and secreted signaling proteins. Our focus is on the Src family tyrosine protein kinases, Hedgehog and Wnt proteins.

View Lab Overview

Research Projects

The Marilyn Resh Lab

Publications

People

Marilyn Resh

Marilyn Resh, PhD

Member

  • Cell biologist Marilyn Resh investigates the regulation of protein function by fatty acylation, and the development of Hedgehog palmitoylation inhibitors to block pancreatic and lung cancer.
  • PhD, Harvard University
  • AB, Princeton University
212-639-2514
Office Phone

Members

Debra Alston
Debra Alston

Sr. Administrative Assistant

James Asciolla
James Asciolla

Graduate Student

Atul Khire, Ph.D.
Atul Khire, Ph.D.

Postdoctoral Fellow

Kalpana Rajanala, PhD
Kalpana Rajanala

Research Fellow

Adina Schonbrun
Adina Schonbrun

Graduate Student

Jing Zhou, Ph.D.
Jing Zhou, Ph.D.

Postdoctoral Fellow

Raisa Louft-Nisenbaum
Raisa Louft-Nisenbaum

Research Technician

Marilyn Resh
Marilyn Resh

Member

Lab Alumni
Rita Curti
Rita Curti

Student Research Assistant

Brittany Haugen
Brittany Haugen

Graduate Student

Armine Matevossian
Armine Matevossian

Principal Scientist at EMD Sero Inc., Cambridge, MA

Lab Affiliations

Achievements

  • Excellence in Teaching and Mentoring Award, Weill Cornell Graduate School (2009)
  • Established Scientist, American Heart Association (1994-1999)
  • Pew Scholar in the Biomedical Sciences, Pew Charitable Trusts (1987-1991)
  • Discovery of the ""two-signal hypothesis"" for binding of myristoylated proteins to membranes
  • Discovery of a myristoyl switch mechanism for membrane binding of HIV-1 Gag
Read more
  • First to establish Hedgehog acyltransferase as a bona fide palmitoyl acyltransferase for Hedgehog proteins
  • Discovery of the first-in-class hedgehog palmitoylation inhibitor

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Marilyn Resh discloses the following relationships and financial interests:

  • Tri-Institutional Therapeutics Discovery Institute
    Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures